Brain Metastases 2.0: Expert Management Strategies and Challenging Cases
Brain metastases are commonly treated as a part of a general neurosurgical practice. Major changes in the management of brain metastases have occurred in the past decade. This webinar covers the management of brain metastases, including:
- Stereotactic Radiosurgery (SR);
- Post-SR Metastases;
- Surgical Resection of BM from Eloquent Cortex;
- Targeted Therapy; and
- Case Presentations Discussing Different Management Strategies.
Upon completion of this activity, participants should be able to:
- Describe advanced management strategies for brain metastases, including resection, stereotactic radiosurgery and immune therapy.
- Describe complex stereotactic radiosurgical planning for large metastases, brainstem metastases and cavities before and after resection.
- Diagnose and manage post-stereotactic radiosurgery (post-SR) brain metastases.
- Describe the advantages and shortcomings of neuroimaging techniques in evaluating post-SR brain metastases.
- Develop an understanding of the role of corticosteroids, bevacizumab and craniotomy in the treatment of post-SR adverse radiation effect/radiation necrosis.
- Describe the current literature on the role of immune therapy as a primary treatment for brain metastases.
The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.
Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.
Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.
|Jeffrey J. Olson, MD, FAANS||Consultant Fees – American Cancer Society|
|Andrew J. Fabiano, MD, FAANS||Grants/Research Support – Arbor Pharmaceuticals Board, Trustee, Officer, Leadership position - Western New York Epilepsy Association, Operation Backbone|
Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.
The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was published in 5/19/2020. Credit may be obtained until 5/19/2023.
|Access Date||Quiz Result||Score||Actions|